Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Standard Of Care Median Survival Of 15 Months

Michael Ciesielski, Phd @mjciesielski Of Roswell Park Cancer Institute Discusses Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Sta... Author: Annual-Meeting Added: 06/06/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts